30 November 2019
CooperVision took its MiSight 1 day: State of the nation roadshow to four cities in October, sharing findings from its latest five-year study and insights from parents.
The roadshows were designed to improve practitioner confidence, capability and communication around contact lenses and myopia management.
Speakers in London, Bristol, Glasgow and Manchester included Dr Fiona Cruickshank from the University of Manchester and Dr Nicola Logan (pictured) from Aston University, who presented findings from CooperVision’s MiSight 1 day’s five-year clinical study.
Insight from CooperVision’s parent survey was presented, which looked at attitudes and concerns in regard to contact lenses and myopia. This was followed by a CET discussion workshop, hosted by optometrist Sarah Morgan on the art of prescribing for myopia.
Director of marketing and national accounts at CooperVision, Mark Draper, said: “Practitioners have said that these events have been extremely valuable in equipping them with the knowledge required to confidently fit and communicate the benefits of MiSight 1 day to parents and patients.”
The contact lens company explained that vision performance remained “excellent” among both groups, with visual acuity of 6/6 at every scheduled appointment, with no significant differences across groups or visits.
It added that there were minimal adverse events and changes in anterior eye clinical observations across both groups.
The roadshows were designed to improve practitioner confidence, capability and communication around contact lenses and myopia management.
Speakers in London, Bristol, Glasgow and Manchester included Dr Fiona Cruickshank from the University of Manchester and Dr Nicola Logan (pictured) from Aston University, who presented findings from CooperVision’s MiSight 1 day’s five-year clinical study.
Insight from CooperVision’s parent survey was presented, which looked at attitudes and concerns in regard to contact lenses and myopia. This was followed by a CET discussion workshop, hosted by optometrist Sarah Morgan on the art of prescribing for myopia.
Director of marketing and national accounts at CooperVision, Mark Draper, said: “Practitioners have said that these events have been extremely valuable in equipping them with the knowledge required to confidently fit and communicate the benefits of MiSight 1 day to parents and patients.”
Clinical study
CooperVision’s latest report from its MiSight 1 day study found that progression rates among the original control group matched the children who had been wearing MiSight 1 day for the entire duration of the study in spherical equivalent refractive error (0.17D) and axial length (0.07mm) during year five.The contact lens company explained that vision performance remained “excellent” among both groups, with visual acuity of 6/6 at every scheduled appointment, with no significant differences across groups or visits.
It added that there were minimal adverse events and changes in anterior eye clinical observations across both groups.
Comments (0)
You must be logged in to join the discussion. Log in